USFDA grants orphan drug status to AstraZeneca's asthma drug Fasenra

AstraZeneca said on Wednesday that the U.S. Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).

EoE, also known as allergic oesophagitis, is an allergic inflammation of the sophagus that involves a form of white blood cell, eosinophils.

Read Also:-AstraZeneca diabetes drug Farxiga meets goal in heart failure trial

AstraZeneca also separately said it met the main goal for its late-stage ETHOS trial for triple-drug therapy Breztri Aerosphere, formerly known as PT010, to treat moderate to very severe chronic obstructive pulmonary disease (COPD)

Read Also:-AstraZeneca gets USFDA fast track status for development of diabetes drug Farxiga